We assist lymphoma patients in identifying study opportunities.
We believe every patient should have the option to participate in the study that is best suited for their medical needs and should NOT be limited based on geographic reach.
When a patient or caregiver contacts us, we will either identify a conveniently located cancer treatment center, request the patient's current physician to open the particular study, or will locate a cancer treatment center and open the site to permit the patient to enroll in the study.
Below is a list of current Lymphoma studies that are available in our network. Our lymphoma studies offerings change frequently and we recommend registering with us to keep you informed about study opportunities.
Lymphoma, Diffuse Large B-Cell
Study Opportunity
Title: Bendamustine with Rituxan® for Adult Patients with Diffuse Large B-Cell Lymphoma
Overview: This study provides Bendamustine (Treanda®) to patients whose cancer has resurfaced or not responded to prior treatments . All eligble patients will receive Treanda® by infusion (plus Rituxan® by infusion on day 1) on days 1 and 2 of each 28-day cycle. Treatment is provided for up to 6 cycles, although treatment will be stopped early if a patient's cancer gets worse or the patient withdraws from the study. Scans to measure response to treatment are according to standard of care, every 8 weeks.
Study Value: Adding Bendamustine to Rituxan® treatment has improved response among patients with other non-Hodgkins lymphomas, with fewer side effects, than standard chemotherapy alone. This study will help define this treatment combination's effect in diffuse large b-cell lymphoma.
Lymphoma, Mantle Cell
Study Opportunity
Title: Bendamustine with Rituxan® for Adult Patients with Mantle Cell Lymphoma
Overview: This study provides Bendamustine (Treanda®) to patients whose cancer has resurfaced or not responded to prior treatments. All eligible patients will receive Treanda® by infusion (plus Rituxan® by infusion on day 1) on days 1 and 2 of each 28-day cycle for up to 6 cycles, although treatment will be stopped if a patient's cancer gets worse or the patient withdraws from the study. Scans to measure response to treatment are according to standard of care.
Study Value: Adding Bendamustine to Rituxan® treatment has increased response among patients with non-Hodgkins lymphomas, with fewer side effects than standard chemotherapy. This study will help define this treatment combination's effect in mantle cell lymphoma.
Lymphoma, Peripheral T-Cell
Study Opportunity
Title: Belinostat® for Adult Patients with Peripheral T-Cell Lymphoma
Overview: This study provides Belinostat® to patients whose cancer has resurfaced or not responded to prior treatments. All eligible patients will receive Belinostat® on days 1 through 5 of each 21-day cycle as long as needed, although treatment will be stopped if a patient's cancer gets worse or the patient withdraws from the study. Scans to measure response to treatment are ordered according to standard of care, every 6 weeks.
Study Value: Belinostat® is in a new class of cancer drug called an HDAC-inhibitor which causes cancer cells to die. It also has little or no bone marrow toxicity which enables patients to more often receive the full dose throughout the trial.
Lymphoma, Follicular or Mantle Cell Non-Hodgkins
Study Opportunity
Title: Phase I/II dose escalation study of the Pan-Histone Deacetylase Inhibitor PCI-24781 in Lymphoma
Overview: The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in lymphoma patients. Study offers monotherapy every other week to follicular or mantle cell lymphoma patients as second-line treatment for up to 12 cycles or until disease relapse.
Study Value: PCI-24781 is well-tolerated including complete absence of prolonged QTc or other cardiac abnormalities.
Disclaimer: The information presented on this website is not intended to be a substitute for professional medical advice
or to replace your relationship with a physician. For all medical concerns, you should always consult your doctor.
Clinical studies listed are those offered by Pharmatech and do not represent all clinical studies available.
